Clinical Benefits: Supports red blood cell formation and helps prevent megaloblastic anaemia Essential for neurological function and nerve tissue health Plays a key role in DNA synthesis and cell metabolism Supports cognitive function, concentration, and mood regulation Assists in the conversion of homocysteine, supporting cardiovascular health Helps address fatigue and weakness associated with B12 deficiency For patients presenting with deficiency, a loading protocol is typically recommended: weekly injections for three weeks, followed by monthly injections for three months, then a maintenance injection every three months

(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB

Free Macro Calculator Personalized daily targets for calories, protein, carbs, and fat
Are skinny shots safe
Immune system support : It helps strengthen the immune system, allowing the body's defenses to function optimally to fight diseases and infections, and recover more quickly from common ailments, making it an essential ally for a healthy life